Trial reportJournal of diabetes2026
Glycated Albumin Guided Therapy in Newly Diagnosed Type 2 Diabetes A Randomized Controlled Trial.
Trial report in Journal of diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05227677 (Value of Glycated Albumin in Intervention of Glycemic Control in Patients With Type 2 Diabetes), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Value of Glycated Albumin in Intervention of Glycemic Control in Patients With Type 2 Diabetes: A Multicenter, Randomized Controlled Clinical Study
Who cites it
3 citing papers in PubMed.
- Glycated Albumin Guided Therapy in Newly Diagnosed Type 2 Diabetes A Randomized Controlled Trial.Journal of diabetes · 2026Trial
- Glycated Albumin-Guided Therapy: Biomarker Utility or Earlier Treatment Intensification?Journal of diabetes · 2026Article
- Response to [Glycated Albumin-Guided Therapy: Biomarker Utility or Earlier Treatment Intensification?].Journal of diabetes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundGlycated albumin (GA) has already been introduced in clinic for decades. However, it remains unclear whether routine measurement of GA could serve as a practical tool to improve the care of patients with type 2 diabetes (T2DM).
methodsThis multicenter, randomized controlled trial enrolled 200 patients with newly diagnosed, poorly controlled type 2 diabetes from seven sites in China. Participants were randomly assigned (1:1) to either GA-guided therapy (treatment intensification if GA > 16% at 4 weeks) or standard therapy, with a 12-weeks follow-up. The primary outcome was the proportion of patients achieving HbA1c < 7%; secondary outcomes included HbA1c < 6.5%, glycemic parameters, hypoglycemia, and β-cell function.
resultsA total of 200 patients were included in this study. Therapy compliances were 97.4% (SD, 5.3%) and 98.0% (SD, 8.2%) in the GA-guided therapy group and standard therapy group, respectively. There was no significant difference in the achievement rate of HbA1c (< 7%) between the GA-guided therapy group (64.3%) and the standard therapy group (64.4%) after the 12-week follow-up (p = 0.99). In the secondary outcome, the achievement rate of HbA1c (< 6.5%) was higher in the GA-guided therapy group than in the standard therapy group (40.5% vs. 25.3%, p = 0.034). Furthermore, the changes in HbA1c, HOMA-β, HOMA-IR, body weight reduction were all better in the GA guided therapy group than in standard therapy group.
conclusionGA-guided therapy did not enhance HbA1c < 7% achievement; however, its potential benefits for more stringent glycemic targets and metabolic parameters in early diabetes management deserve further investigation.
trial registrationClinicalTrials.gov: NCT05227677.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.